MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Vernalis plc Company Profile (LON:VER)

Consensus Ratings for Vernalis plc (LON:VER) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: GBX 84

Analysts' Ratings History for Vernalis plc (LON:VER)
Show:
DateFirmActionRatingPrice TargetActions
6/24/2016Stifel NicolausReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2016Canaccord GenuityReiterated RatingBuyGBX 84View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/13/2016Shore CapitalReiterated Ratinghouse stockView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/17/2016Panmure GordonReiterated RatingBuyGBX 91View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/21/2015N+1 SingerReiterated RatingBuyGBX 86View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2015Oriel Securities LtdReiterated RatingBuyGBX 63View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for Vernalis plc (LON:VER)
No earnings announcements for this company have been tracked by MarketBeat.com

Earnings Estimates for Vernalis plc (LON:VER)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Vernalis plc (LON:VER)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Vernalis plc (LON:VER)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/9/2016Mackney,DavidInsiderBuy97,000GBX 45£43,650Tweet This Trade  Share This Trade on StockTwits
5/5/2015Nigel SheailInsiderBuy84,000GBX 59.90£50,316Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Vernalis plc (LON:VER)
DateHeadline
06/24/16 09:43 AMVernalis PLC (LON:VER) target price held steady to GBX0 as issued in a report today by Stifel
06/20/16 08:28 AMAttention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market : Size, Application Analysis, Regional Outlook to 2021
06/09/16 07:42 PMDIRECTOR DEALINGS: Vernalis CEO And CFO Buy Shares
05/31/16 07:33 PMRenishaw plc (LON:RSW) Given Average Recommendation of "Hold" from Analysts - ... are outstanding with shareholders and have a share price of 326.7 bringing St Modwen Properties PLC's market capitalisation to 722.61M GBP. Vernalis plc (LON:VER) has declined 39.46% since October 28, 2015 and is downtrending. The stock's 50 day ...
05/19/16 11:56 AMMoxatag supply issues looming for Vernalis -
05/19/16 10:32 AMMoxatag Supply Update - [at noodls] - 19 May 2016 LSE: VER Vernalis plc ('Vernalis' or the 'Company') was informed yesterday that Suir Pharma Limited ('Suir') of Clonmel Ireland, the sole source supplier of finished dosage form Moxatag®, has ...
03/14/16 01:22 PMVernalis plc : half-yearly earnings release - The company will report its earnings for S1 2016 on 03/17/2016. Generally, the company reports earnings better than estimates. In recent months, the 2 analysts from Thomson Reuters consensus have revised their EPS estimates downward.
03/11/16 03:35 AMVernalis Plc breached its 50 day moving average in a Bearish Manner : VER-GB : March 11, 2016 -
03/01/16 03:34 AMVernalis Plc breached its 50 day moving average in a Bullish Manner : VER-GB : March 1, 2016 -
02/04/16 10:19 AMVernalis plc ("Vernalis" or the "Company") Notice of Results for the Six Months Ended 31 December 2015 - [Marketwired] - Vernalis plc announces its unaudited interim results for the six months ended 31 December 2015 will be released on Thursday, 17 March 2016. The results announcement will be distributed at 7:00 am and will ...
01/28/16 12:22 PMAttention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015 - Research and Markets - Inc. Vernalis Plc For more information visit http://www.researchandmarkets.com/research/nvk3pf/attention_deficit View source version on businesswire.com: http://www.businesswire.com/news/home/20160128005691/en/ Personal Investing Ideas & Strategies ...
01/09/16 10:41 AMVernalis Announces Adenosine Antagonist Licensee - [at noodls] - RNS Number : 9252K Vernalis PLC as its Worldwide Licensee for their Adenosine Antagonist Program Adenosine antagonists under development for use in immuno-oncology ('Vernalis' or the 'Company') today announces ...
01/07/16 03:35 AMVernalis Plc breached its 50 day moving average in a Bearish Manner : January 7, 2016 -
01/06/16 01:17 AMVernalis Announces Corvus Pharmaceuticals, Inc. as its Worldwide Licensee for their Adenosine Antagonist Program - [at noodls] - 6 January 2016 LSE: VER Adenosine antagonists under development for use in immuno-oncology Vernalis plc ('Vernalis' or the 'Company') today announces Corvus Pharmaceuticals, Inc. ('Corvus') as its licensee ...
12/21/15 03:33 AMVernalis Plc breached its 50 day moving average in a Bearish Manner : December 21, 2015 -
12/21/15 01:35 AMVernalis Announces Successful Completion of CCP-07 Pivotal Single-Dose Comparative Bioavailability Study - [at noodls] - 21 December 2015 LSE: VER Vernalis Announces Successful Completion of CCP-07 Pivotal Single-Dose Comparative Bioavailability Study FDA NDA filing remains on track for 2016 Vernalis plc ('Vernalis' or the ...
12/21/15 01:13 AMVernalis Announce CCP-07 Single-Dose Study Results - [at noodls] - LSE: VER Vernalis Announces Successful Completion of CCP-07 Pivotal Single-Dose Comparative Bioavailability Study FDA NDA filing remains on track for 2016 ('Vernalis' or the 'Company') today announces ...
12/08/15 03:34 AMVernalis Plc breached its 50 day moving average in a Bearish Manner : December 8, 2015 -
12/03/15 11:32 AMLaunch of 2015 Sharesave Plan - [at noodls] - 3 December 2015 Vernalis plc ('Vernalis' or the 'Company') Vernalis plc is pleased to announce that, on 2 December 2015, it launched a new Sharesave Plan (previously known as a Save As You Earn or SAYE ...
12/02/15 05:34 AMVernalis Results of Annual General Meeting - [at noodls] - 2 December 2015 LSE: VER Resolutions Vernalis plc (LSE: VER) announces that all resolutions proposed to shareholders at its Annual General Meeting held today were duly passed. All resolutions were approved ...
12/02/15 01:00 AMVernalis plc ("Vernalis" or the "Company") AGM Statement - [Marketwired] - Vernalis plc will hold its Annual General Meeting in London at 10.30am today. The Company issues the following statement ahead of the AGM:
About Vernalis plc

Vernalis plc logoVernalis plc is a commercial-stage pharmaceutical holding company. The Company is engaged in the research, development and commercialization of pharmaceutical products for a range of medical disorders. The Company has two marketed products: Tuzistra XR in the United States prescription cough cold market, and frovatriptan, an acute treatment for migraine. The Company also has four prescription cough cold products under development, and a pipeline of research and new chemical entity (NCE) development programs. Its commercial pipeline candidates include CCP-05, CCP-06, CCP-07 and CCP-08. The Company operates in the United Kingdom, Rest of Europe, North America and Rest of the World. The Company is also engaged in fragment- and structure-based drug discovery. It has two development products in the central nervous system (CNS) therapeutic area: the fatty acid amide hydrolase (FAAH) inhibitor V158866 for pain, and V81444, an adenosine A2A receptor antagonist as a treatment for CNS diseases.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: VER
  • CUSIP:
Key Metrics:
  • Previous Close: $0.49
  • 50 Day Moving Average: $44.34
  • 200 Day Moving Average: $54.37
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $162.43M
  • Current Quarter EPS Consensus Estimate: $-5.57 EPS
Additional Links:

            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha